Pyruvate Kinase Deficiency (PKLR) Sequencing

Interpretive Data: Background information for Pyruvate Kinase Deficiency (PKLR) Sequencing:
Characteristics: Red cell pyruvate kinase (PK) deficiency, although relatively rare, is the most common glycolytic defect resulting in congenital non-spherocytic hemolytic anemia. Clinical features of PK deficiency are highly variable, ranging from well compensated anemia to severe disease with lifelong transfusion dependency. Other clinical manifestations may include jaundice, gallstones, iron overload and potential for other complications.
Prevalence: Varies by ethnicity; 1 in 20,000 Caucasians, higher prevalence in Pennsylvania Amish and Romani.
Inheritance: Autosomal recessive.
Cause: Pathogenic biallelic germline variants in PKLR.
Clinical Sensitivity: 98 percent.
Methodology: Bidirectional sequencing of all coding regions, intron/exon boundaries, 5' untranslated region and deep intronic variants c.1269+43T>C and c.1269+44C>T (also known as IVS9+43T>C and IVS9+44C>T, respectively) of the PKLR gene.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations or repeat element insertions. Deep intronic variants other than those targeted and large deletions/duplications will not be detected. Regulatory region variants outside of the 5' untranslated region will not be assessed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.